Tags

Type your tag names separated by a space and hit enter

Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.

Abstract

BACKGROUND

Selenium and coenzyme Q10 are essential for the cell. Low cardiac contents of selenium and coenzyme Q10 have been shown in patients with cardiomyopathy, but inconsistent results are published on the effect of supplementation of the two components separately. A vital relationship exists between the two substances to obtain optimal function of the cell. However, reports on combined supplements are lacking.

METHODS

A 5-year prospective randomized double-blind placebo-controlled trial among Swedish citizens aged 70 to 88 was performed in 443 participants given combined supplementation of selenium and coenzyme Q10 or a placebo. Clinical examinations, echocardiography and biomarker measurements were performed. Participants were monitored every 6th month throughout the intervention. The cardiac biomarker N-terminal proBNP (NT-proBNP) and echocardiographic changes were monitored and mortalities were registered. End-points of mortality were evaluated by Kaplan-Meier plots and Cox proportional hazard ratios were adjusted for potential confounding factors. Intention-to-treat and per-protocol analyses were applied.

RESULTS

During a follow up time of 5.2 years a significant reduction of cardiovascular mortality was found in the active treatment group vs. the placebo group (5.9% vs. 12.6%; P=0.015). NT-proBNP levels were significantly lower in the active group compared with the placebo group (mean values: 214 ng/L vs. 302 ng/L at 48 months; P=0.014). In echocardiography a significant better cardiac function score was found in the active supplementation compared to the placebo group (P=0.03).

CONCLUSION

Long-term supplementation of selenium/coenzyme Q10 reduces cardiovascular mortality. The positive effects could also be seen in NT-proBNP levels and on echocardiography.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Cardiovascular Medicine, Department of Medicine and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden. Urban.Alehagen@liu.se

    , , ,

    Source

    International journal of cardiology 167:5 2013 Sep 01 pg 1860-6

    MeSH

    Aged
    Aged, 80 and over
    Biomarkers
    Cardiovascular Diseases
    Cohort Studies
    Dietary Supplements
    Double-Blind Method
    Drug Therapy, Combination
    Female
    Humans
    Male
    Natriuretic Peptide, Brain
    Peptide Fragments
    Prospective Studies
    Selenium
    Sweden
    Ubiquinone

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22626835

    Citation

    Alehagen, Urban, et al. "Cardiovascular Mortality and N-terminal-proBNP Reduced After Combined Selenium and Coenzyme Q10 Supplementation: a 5-year Prospective Randomized Double-blind Placebo-controlled Trial Among Elderly Swedish Citizens." International Journal of Cardiology, vol. 167, no. 5, 2013, pp. 1860-6.
    Alehagen U, Johansson P, Björnstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013;167(5):1860-6.
    Alehagen, U., Johansson, P., Björnstedt, M., Rosén, A., & Dahlström, U. (2013). Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International Journal of Cardiology, 167(5), pp. 1860-6. doi:10.1016/j.ijcard.2012.04.156.
    Alehagen U, et al. Cardiovascular Mortality and N-terminal-proBNP Reduced After Combined Selenium and Coenzyme Q10 Supplementation: a 5-year Prospective Randomized Double-blind Placebo-controlled Trial Among Elderly Swedish Citizens. Int J Cardiol. 2013 Sep 1;167(5):1860-6. PubMed PMID: 22626835.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. AU - Alehagen,Urban, AU - Johansson,Peter, AU - Björnstedt,Mikael, AU - Rosén,Anders, AU - Dahlström,Ulf, Y1 - 2012/05/23/ PY - 2012/01/10/received PY - 2012/04/17/revised PY - 2012/04/28/accepted PY - 2012/5/26/entrez PY - 2012/5/26/pubmed PY - 2014/4/23/medline KW - Cardiovascular mortality KW - Coenzyme Q10 KW - Dietary supplementation KW - Elderly KW - NT-proBNP KW - Selenium SP - 1860 EP - 6 JF - International journal of cardiology JO - Int. J. Cardiol. VL - 167 IS - 5 N2 - BACKGROUND: Selenium and coenzyme Q10 are essential for the cell. Low cardiac contents of selenium and coenzyme Q10 have been shown in patients with cardiomyopathy, but inconsistent results are published on the effect of supplementation of the two components separately. A vital relationship exists between the two substances to obtain optimal function of the cell. However, reports on combined supplements are lacking. METHODS: A 5-year prospective randomized double-blind placebo-controlled trial among Swedish citizens aged 70 to 88 was performed in 443 participants given combined supplementation of selenium and coenzyme Q10 or a placebo. Clinical examinations, echocardiography and biomarker measurements were performed. Participants were monitored every 6th month throughout the intervention. The cardiac biomarker N-terminal proBNP (NT-proBNP) and echocardiographic changes were monitored and mortalities were registered. End-points of mortality were evaluated by Kaplan-Meier plots and Cox proportional hazard ratios were adjusted for potential confounding factors. Intention-to-treat and per-protocol analyses were applied. RESULTS: During a follow up time of 5.2 years a significant reduction of cardiovascular mortality was found in the active treatment group vs. the placebo group (5.9% vs. 12.6%; P=0.015). NT-proBNP levels were significantly lower in the active group compared with the placebo group (mean values: 214 ng/L vs. 302 ng/L at 48 months; P=0.014). In echocardiography a significant better cardiac function score was found in the active supplementation compared to the placebo group (P=0.03). CONCLUSION: Long-term supplementation of selenium/coenzyme Q10 reduces cardiovascular mortality. The positive effects could also be seen in NT-proBNP levels and on echocardiography. SN - 1874-1754 UR - https://www.unboundmedicine.com/medline/citation/22626835/Cardiovascular_mortality_and_N_terminal_proBNP_reduced_after_combined_selenium_and_coenzyme_Q10_supplementation:_a_5_year_prospective_randomized_double_blind_placebo_controlled_trial_among_elderly_Swedish_citizens_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-5273(12)00593-1 DB - PRIME DP - Unbound Medicine ER -